Use of gamma-linolenic acid in the treatment of schizophrenia and tardive dyskinesia.
There is good background evidence to suggest that essential fatty acids and their eicosanoid derivatives may play a role in schizophrenia and in with tardive dyskinesia. Trials involving treatment with essential fatty acids, or eicosanoids or drugs which stimulate eicosanoid synthesis have shown modestly promising results. Particularly favourable outcomes in both schizophrenia and tardive dyskinesia were associated with combined treatment using essential fatty acids and nutritional supplements.
Vaddadi
K S
KS
Larundel Hospital, Bundoora, Victoria, Australia.
D000328:Adult; D000527:Alprostadil / Q000096:biosynthesis / Q000172:deficiency*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000378:metabolism; D015777:Eicosanoids / Q000096:biosynthesis / Q000502:physiology; D005228:Fatty Acids, Essential / Q000378:metabolism; D006801:Humans; D008042:Linolenic Acids / Q000627:therapeutic use*; D008043:Linseed Oil / Q000627:therapeutic use; D008875:Middle Aged; D008959:Models, Neurological; D010404:Penicillin V / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome; D017965:gamma-Linolenic Acid
D015777:Eicosanoids; D005228:Fatty Acids, Essential; D008042:Linolenic Acids; D017965:gamma-Linolenic Acid; D008043:Linseed Oil; D000527:Alprostadil; D010404:Penicillin V